A standard dose of linezolid puts patients with hepatic impairment at risk of overexposure
- 25 November 2022
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Clinical Pharmacology
- Vol. 79 (1), 149-157
- https://doi.org/10.1007/s00228-022-03427-7
Abstract
Purpose The purpose of this retrospective observational study conducted in patients with hepatic impairment was to assess the variability of linezolid trough concentrations, to determine the risk factors for linezolid overexposure, and to investigate the effect of linezolid overexposure on linezolid-induced thrombocytopenia. Methods All enrolled patients received a standard dose (600 mg every 12 h) of linezolid and underwent therapeutic drug monitoring. The Child–Pugh-Turcotte score was used to divide patients into three groups: mild, moderate, and severe hepatic impairment. The risk factors for linezolid overexposure (Cmin > 8 mg/L) and linezolid-induced thrombocytopenia were examined using logistic regression. And the Kaplan–Meier curve was used to describe the association between linezolid overexposure and linezolid-induced thrombocytopenia. Results Seventy-seven patients were included, 37 (48.1%) of whom experienced linezolid overexposure. Patients with severe hepatic impairment had a substantially higher median Cmin of linezolid than those with mild (20.7 mg/L vs 5.51 mg/L, P < 0.001) or moderate (20.7 mg/L vs 6.70 mg/L, P = 0.001) hepatic impairment. Severe hepatic impairment was significantly associated with linezolid overexposure (OR 7.037, 95%CI 1.426–34.727, P = 0.017). After linezolid treatment, linezolid-induced thrombocytopenia occurred in 32 (41.6%) patients, and Cmin > 8 mg/L was a significant predictor of linezolid-induced thrombocytopenia (OR 3.024, 95%CI 1.083–8.541, P = 0.035). Conclusion Patients with hepatic impairment who received standard doses of linezolid are at greater risk of linezolid overexposure, which may lead to a higher incidence of linezolid-induced thrombocytopenia.Keywords
This publication has 35 references indexed in Scilit:
- High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopeniaJournal of Antimicrobial Chemotherapy, 2013
- Clinical pharmacokinetic/pharmacodynamic profile of linezolid in severely ill Intensive Care Unit patientsInternational Journal of Antimicrobial Agents, 2011
- Population Pharmacokinetic and Pharmacodynamic Analysis of Linezolid and a Hematologic Side Effect, Thrombocytopenia, in Japanese PatientsAntimicrobial Agents and Chemotherapy, 2011
- Therapeutic Drug Monitoring of Linezolid: a Retrospective Monocentric AnalysisAntimicrobial Agents and Chemotherapy, 2010
- Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunctionInternational Journal of Antimicrobial Agents, 2010
- Penetration of Linezolid into Soft Tissues of Healthy Volunteers after Single and Multiple DosesAntimicrobial Agents and Chemotherapy, 2005
- Linezolid in vitro: mechanism and antibacterial spectrumJournal of Antimicrobial Chemotherapy, 2003
- Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infectionsJournal of Antimicrobial Chemotherapy, 2003
- Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteersJournal of Antimicrobial Chemotherapy, 2003
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976